Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | XmAb18087 |
| Trade Name | |
| Synonyms | XmAb 18087|XmAb-18087|Tidutamab |
| Drug Descriptions |
XmAb18087 (Tidutamab) is a bispecific monoclonal antibody that targets CD3 and somatostatin receptor 2 (SSTR2), which once bound to tumor cells expressing SSTR2, may elicit an immune response, resulting in cell death (NCI Drug Dictionary). |
| DrugClasses | CD3 Antibody 119 |
| CAS Registry Number | 2148354-90-7 |
| NCIT ID | C146820 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Pembrolizumab + XmAb18087 | Pembrolizumab XmAb18087 | 0 | 1 |
| XmAb18087 | XmAb18087 | 0 | 2 |